SV1998000131A - Formulaciones de accion prolongada ref. ahp-95011-1-c1 - Google Patents

Formulaciones de accion prolongada ref. ahp-95011-1-c1

Info

Publication number
SV1998000131A
SV1998000131A SV1998000131A SV1998000131A SV1998000131A SV 1998000131 A SV1998000131 A SV 1998000131A SV 1998000131 A SV1998000131 A SV 1998000131A SV 1998000131 A SV1998000131 A SV 1998000131A SV 1998000131 A SV1998000131 A SV 1998000131A
Authority
SV
El Salvador
Prior art keywords
prolonged
ahp
formulations
prolonged action
offers
Prior art date
Application number
SV1998000131A
Other languages
English (en)
Inventor
Deborah M Sherman
John Ulrick Lamer
John Clifton Clark
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25508423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV1998000131(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SV1998000131A publication Critical patent/SV1998000131A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE RELACIONA CON UNA FOMULA POSOLOGICA Y DOSIS UNITARIA DE LA MISMA, CLORHIDRATO DE VENLAFAXINA, UN AGENTE ANTIDEPRRESIVO, DE LIBERACION PROLONGADA SOBRE 24 HORAS, QUE OFRECE UN CONTROL MEJOR DE LAS CONCENTRACIONES PLASMATICAS QUE EL DE LAS FOMULAS CONVENCIONALES EN TABLETAS QUE DEBEN ADMINISTRARSE DOS O MAS VECES AL DIA, Y QUE TAMBIEN SE ASOCIA CON UNA INCIDENCIA MENOR DE NAUSEAS Y VOMITOS QUE LAS TABLETAS CONVENCIONALES, EN SU ASPECTO PRIMARIO, ESTA INVENCION OFRECE UN NUCLEO MEJORADO DE LOS ESFEROIDES DE LIBERACION PROLONGADA, QUE COMPRENDE CLORHIDRATO DE VENTAFAXINA Y CELULOSA MICROCRISTALINA, ES DECIR EL AGREGADO DE HIDROPROPILMETILCELULOSA
SV1998000131A 1997-11-05 1998-11-04 Formulaciones de accion prolongada ref. ahp-95011-1-c1 SV1998000131A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96432897A 1997-11-05 1997-11-05

Publications (1)

Publication Number Publication Date
SV1998000131A true SV1998000131A (es) 1999-11-18

Family

ID=25508423

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1998000131A SV1998000131A (es) 1997-11-05 1998-11-04 Formulaciones de accion prolongada ref. ahp-95011-1-c1

Country Status (39)

Country Link
EP (1) EP1028718B1 (es)
JP (1) JP2001521892A (es)
KR (1) KR20010031797A (es)
CN (1) CN1278165A (es)
AR (1) AR014012A1 (es)
AT (1) ATE237320T1 (es)
AU (1) AU747978B2 (es)
BG (1) BG104397A (es)
BR (1) BR9813179A (es)
CA (1) CA2305242A1 (es)
CL (1) CL2004001705A1 (es)
CO (1) CO5011060A1 (es)
CZ (1) CZ20001659A3 (es)
DE (1) DE69813602T2 (es)
DK (1) DK1028718T3 (es)
EA (1) EA200000487A1 (es)
EE (1) EE04577B1 (es)
ES (1) ES2196620T3 (es)
GE (1) GEP20043198B (es)
HK (1) HK1029056A1 (es)
HR (1) HRP20000213B1 (es)
HU (1) HU225238B1 (es)
ID (1) ID26317A (es)
IL (1) IL135457A0 (es)
MA (1) MA24691A1 (es)
NO (1) NO20002126L (es)
NZ (1) NZ504460A (es)
PA (1) PA8462501A1 (es)
PE (1) PE128699A1 (es)
PL (1) PL341141A1 (es)
PT (1) PT1028718E (es)
SK (1) SK6472000A3 (es)
SV (1) SV1998000131A (es)
TR (1) TR200001232T2 (es)
TW (1) TW555568B (es)
UA (1) UA77145C2 (es)
UY (2) UY25234A1 (es)
WO (1) WO1999022724A2 (es)
ZA (1) ZA9810081B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003521470A (ja) * 1999-04-06 2003-07-15 セプラコア インコーポレーテッド ベンラファキシンの誘導体とその調製および使用方法
ES2290027T3 (es) * 1999-05-20 2008-02-16 Elan Corporation, Plc Formulaciones multiparticuladas y de liberacion controlada de inhibidores selectivos de la recaptacion de serotonina.
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
HUP0402524A2 (hu) * 2001-12-05 2005-03-29 Wyeth Venlafaxin-hidroklorid kristályos polimorf formája, eljárások előállítására, az ezt tartalmazó gyógyszerkészítmények és alkalmazásuk
AU2002247945A1 (en) * 2001-12-13 2003-06-23 Cadila Healthcare Limited Manufacture of venlafaxine hydrochloride and crystalline polymorphs thereof
WO2003055475A1 (en) * 2002-01-03 2003-07-10 Lek Pharmaceutical And Chemical Company D.D. Controlled release pharmaceutical formulation containing venlafaxine
WO2003082261A1 (en) * 2002-03-28 2003-10-09 Synthon B.V. Extended release venlafaxine formulations
AU2003226748A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Compositions of venlafaxine base
WO2003082805A1 (en) 2002-03-28 2003-10-09 Synthon B.V. Low water-soluble venlafaxine salts
US6717015B2 (en) 2002-03-28 2004-04-06 Synthon Bv Venlafaxine besylate
FR2845289B1 (fr) 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
DE10350194B4 (de) * 2003-10-28 2005-11-10 Bioplanta Arzneimittel Gmbh Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
SI1502587T1 (sl) * 2003-07-30 2007-02-28 Pharmathen Sa Formulacija z zadrzevanim sproscanjem za Venlafaxin hidroklorid
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
EP1711169B1 (en) 2004-02-04 2007-05-09 Alembic Limited Extended release coated minitablets of venlafaxine hydrochloride
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
CA2648278C (en) * 2006-04-03 2019-05-28 Isa Odidi Drug delivery composition
WO2007129329A2 (en) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
CN102772390B (zh) * 2012-08-16 2014-01-08 乐普药业股份有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
FR3080278B1 (fr) * 2018-04-11 2021-04-30 Ghs Patents Ltd Procede de fabrication d'un spheroide de cannabidiol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
NO20002126L (no) 2000-05-04
PT1028718E (pt) 2003-07-31
UY25692A1 (es) 2000-03-31
WO1999022724A3 (en) 1999-07-22
JP2001521892A (ja) 2001-11-13
PE128699A1 (es) 2000-01-06
NO20002126D0 (no) 2000-04-26
NZ504460A (en) 2003-01-31
AU1300399A (en) 1999-05-24
ID26317A (id) 2000-12-14
CL2004001705A1 (es) 2005-06-03
UY25234A1 (es) 2000-12-29
HRP20000213B1 (en) 2004-04-30
DE69813602T2 (de) 2003-11-06
AU747978B2 (en) 2002-05-30
MA24691A1 (fr) 1999-07-01
BG104397A (en) 2001-02-28
ZA9810081B (en) 2000-05-04
TW555568B (en) 2003-10-01
PL341141A1 (en) 2001-03-26
HU225238B1 (en) 2006-08-28
EP1028718A2 (en) 2000-08-23
DK1028718T3 (da) 2003-07-28
EP1028718B1 (en) 2003-04-16
TR200001232T2 (tr) 2000-12-21
IL135457A0 (en) 2001-05-20
WO1999022724A2 (en) 1999-05-14
HUP0004287A2 (hu) 2002-04-29
CN1278165A (zh) 2000-12-27
DE69813602D1 (de) 2003-05-22
SK6472000A3 (en) 2000-11-07
ES2196620T3 (es) 2003-12-16
ATE237320T1 (de) 2003-05-15
HUP0004287A3 (en) 2002-05-28
KR20010031797A (ko) 2001-04-16
EA200000487A1 (ru) 2000-10-30
AR014012A1 (es) 2001-01-31
HRP20000213A2 (en) 2000-12-31
PA8462501A1 (es) 2000-05-24
CO5011060A1 (es) 2001-02-28
GEP20043198B (en) 2004-03-25
EE200000212A (et) 2001-04-16
EE04577B1 (et) 2006-02-15
UA77145C2 (en) 2006-11-15
HK1029056A1 (en) 2001-03-23
BR9813179A (pt) 2000-08-22
CA2305242A1 (en) 1999-05-14
CZ20001659A3 (cs) 2001-10-17

Similar Documents

Publication Publication Date Title
SV1998000131A (es) Formulaciones de accion prolongada ref. ahp-95011-1-c1
AR006519A1 (es) Formula encapsulada de liberacion prolongada de clorhidrato de venlafaxina, una formula de pelicula de recubrimiento, y el uso de dicha formula encapsuladapara preparar una formulacion de liberacion prolongada
PT1121104E (pt) Novas formulacoes orais de libertacao controlada
AR002754A1 (es) Composición farmacéutica que comprende bacterias lactobacillus viables micro-encapsuladas, y uso de la composición para preparar de un medicamento
AP2397A (en) Matrix for sustained, invariant and independent release of active compounds.
MX9402938A (es) Composicion terapeutica que comprende nicotinamida-adenina-dinucleotido ynicotinamida-adenina-fosfato-dinucleotido, estable ingerible y absorbible.
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
PE20070192A1 (es) Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
CO4750836A1 (es) Nuevos medicamentos y utilizacion (1-metiletil)-8-azoniabiciclo-[3.2.1]octnao y su uso en pre- paraciones medicas
BRPI0316616B8 (pt) emplastro térmico com efeito térmico suficiente que torna a sensação agradável mais duradoura e irritação residual mais reduzida
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
PT1073467E (pt) Formulacoes de co-solvente que compreendem um composo de vitamina d.
ES2065647T3 (es) Empleo cosmetico de una composicion que tiene una actividad antieritematosa.
PE17897A1 (es) Formulacion transdermica en parche del 3-(4-butiltio)-1,2,5-tiadiazol-3-il)-1-azabiciclo (2,2,2) octano
ES2171669T3 (es) Composicion farmaceutica que contiene hidrocloruro de tiagabina y su procedimiento de preparacion.
ES2305567T3 (es) Formulaciones de tramadol de liberacion sostenida con una eficacia de 24 horas.
ES2127610T3 (es) Composiciones cosmeticas fotoprotectoras que contienen nanopigmentos de tio2 y un acilaminoacido.
AR016473A1 (es) Preparado efervescente y procedimiento para su preparacion
BR9810996A (pt) Composição farmacêutica
ES2033181B1 (es) Una tableta o capsula de herbicida para su aplicacion en arrozales.
ECSP972046A (es) Formula de liberacion prolongada
AR040764A1 (es) Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina
ECSP982704A (es) Formula de liberacion prolongada
ES2078727T3 (es) Composiciones farmaceuticas.
IT1257479B (it) Derivati prostaglandinici aventi effetti radioprotettivi

Legal Events

Date Code Title Description
FG Grant
FD Lapse